PF-5212374

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NamePF-5212374
Drug Alias NamePF-5212374TRU-015
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, RheumatoidLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEmergent
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth LlcPfizer Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicArthritis, RheumatoidLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A